DT Investment Partners LLC increased its position in Pfizer, Inc. (NYSE:PFE) by 19.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,118 shares of the biopharmaceutical company’s stock after purchasing an additional 7,526 shares during the period. DT Investment Partners LLC’s holdings in Pfizer were worth $1,549,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of PFE. Northstar Group Inc. grew its stake in shares of Pfizer by 0.4% in the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 35 shares during the last quarter. Meridian Wealth Management LLC grew its stake in shares of Pfizer by 0.5% in the second quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock worth $402,000 after acquiring an additional 57 shares during the last quarter. Stone House Investment Management LLC grew its stake in shares of Pfizer by 0.9% in the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock worth $245,000 after acquiring an additional 66 shares during the last quarter. Naples Global Advisors LLC grew its stake in shares of Pfizer by 0.3% in the first quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock worth $840,000 after acquiring an additional 79 shares during the last quarter. Finally, Asset Planning Services Ltd. grew its stake in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 137 shares during the last quarter. 68.98% of the stock is currently owned by institutional investors.

In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Sally Susman sold 38,230 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total value of $1,338,050.00. Following the sale, the insider now owns 145,649 shares in the company, valued at approximately $5,097,715. The disclosure for this sale can be found here. In the last quarter, insiders have sold 464,521 shares of company stock worth $15,813,961. Company insiders own 0.06% of the company’s stock.

Pfizer, Inc. (PFE) opened at 36.20 on Wednesday. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $36.60. The company has a market cap of $215.29 billion, a P/E ratio of 26.48 and a beta of 1.00. The firm has a 50-day moving average price of $35.25 and a 200-day moving average price of $33.76.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the previous year, the business earned $0.64 EPS. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. On average, analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.54%. Pfizer’s payout ratio is presently 94.12%.

ILLEGAL ACTIVITY NOTICE: “DT Investment Partners LLC Purchases 7,526 Shares of Pfizer, Inc. (PFE)” was posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.dailypolitical.com/2017/10/18/dt-investment-partners-llc-purchases-7526-shares-of-pfizer-inc-pfe.html.

PFE has been the topic of a number of recent research reports. Cowen and Company set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Monday, August 14th. UBS AG reissued a “buy” rating and issued a $38.00 target price on shares of Pfizer in a research note on Monday, July 31st. Sanford C. Bernstein set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Monday, July 17th. BMO Capital Markets reissued a “buy” rating and issued a $37.00 target price on shares of Pfizer in a research note on Wednesday, September 6th. Finally, Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $38.15.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.